A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Recruiting now Phase 3 NCT07222332
Run by Eli Lilly and Company · for 1 to 35 · All sexes
What this study is about
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Who can join (things the study team will check)
✅ You may be able to join if…
- Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention
- Have at least one diabetes-related autoantibody found at screening
- Show signs of remaining beta-cell function
- stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening
- Weigh at least 8 kilograms (kg) (18 pounds) at screening
🚫 You may not be able to join if…
- Have any other type of diabetes including gestational
- Have uncontrolled high blood pressure
- Have had a heart attack, heart disease, stroke, or heart failure
- Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
- Have a current or recent clinically serious medical condition or infection
Where this trial is running
- Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States
- Tallahassee Memorial HealthCare, Tallahassee, Florida, United States
- Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
- Driscoll Children's Hospital, Corpus Christi, Texas, United States
- University of Virginia, Charlottesville, Virginia, United States
- Women's and Children's Hospital, Adelaide, Australia
- Centre for Children's Health Research, Brisbane, Australia
- Austin Health - Repatriation Hospital, Heidelberg West, Australia
- Ipswich Hospital, Ipswich, Australia
- Royal Children's Hospital, Melbourne, Australia
- Southern Adelaide Diabetes & Endocrine Services, Oaklands Park, Australia
- The Royal Melbourne Hospital, Parkville, Australia
+ 121 more sites.
Who to contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07222332.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.